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↑What is “already known” in this topic: 
Previous studies have investigated the challenges of clinical trials 
only in the conducting step. Most of these studies reported 
challenges in developing countries.   
 
→What this article adds: 
This study provided a comprehensive review of the challenges of 
clinical trial studies in different steps including design, 
conducting, analysis, and reporting in both developing and 
developed countries.  
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Abstract 
    Background: Randomized clinical trials have been considered as the gold standard for evaluating the effectiveness and safety of 
medical interventions; however, there are major barriers to their design, conduct, analysis, and reporting. They are multidisciplinary 
and involve different steps and face a variety of challenges that may vary from one country to another. The aim of this study was to 
provide a comprehensive presentation of the challenges of clinical trial studies in different steps including design, conducting, analysis, 
and reporting. 
   Methods: In this study, all original articles conducted during 1991-2017 that reviewed the barriers to clinical trial studies at one of 
the steps of design, conducing, analysis, and reporting of the results in Medline (through PubMed), Embase, Web of Sciences, Scopus, 
and Google Scholar were considered. The searched keywords were as follow: challenges, barriers, and randomized clinical trial. 
   Results: The following barriers in different steps of randomized clinical trials were identified: general barriers include insufficient 
knowledge and understanding of clinical research and research methodology, barriers to ethical and regulatory systems, and lack of 
funding. The investigator-initiated trials may face similar problems to those of sponsor-initiated trials, such as handling regulatory 
systems, administrative and financial issues, multiple languages, and different patient compensation approaches. The challenge related 
to design was poor planning. Other challenges were lack of manpower and financial resources, inappropriate statistical methods for 
analysis (analysis challenges), and challenges related to reporting which include selective reporting. 
   Conclusion: Based on the results of this systematic review, the most important challenges were barriers related to handling ethical 
and regulatory systems, patient recruitment, and lack of budget and skilled staff for conducting clinical trials. Training to improve the 
quality of randomized clinical trial studies in different steps and levels was the most important recommendation in these studies. 
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Introduction 
 
Randomized clinical trials (RCTs) are considered as the 
gold standard for evaluating the effectiveness and safety 
of medical interventions (1). These types of studies are 
known as the basis for evidence-based decision making 
and the gold standard for clinical research. In recent years, 
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a major scientific revolution to decide on evidence-based 
health care has led to the development of clinical trials (2). 
A well-conducted randomized clinical trial can be the 
most reliable method for measuring the effectiveness of 
clinical interventions (3).  
Although clinical trial studies have been considered as 
the gold standard, the emphasis on the quality of these 
studies for their effects has always been taken into ac-
count. These studies are multidisciplinary and involve 
different steps, so they may face a variety of challenges 
that vary from one country to another. 
One of the basic principles for conducting a clinical trial 
is that the collected data should be monitored; such regu-
lar monitoring helps to ensure that the risks to the partici-
pants are not more than expected and the study is done 
properly (4). Many universities have less awareness of the 
research priorities of clinical studies (5). Conducting these 
studies in developing countries often causes ethical, or-
ganizational, cultural, and infrastructural barriers for re-
searchers, pharmaceutical companies, sponsors, and regu-
latory agencies (2). 
Due to the unique social and economic conditions of In-
dia (low literacy, poverty, lack of public medical facili-
ties) and the unique relationships between doctors and 
patients in this country, patients are exposed to the most 
vulnerable conditions in the process of clinical trials. The 
main concerns are related to the process of obtaining in-
formed consent and compensation for participants due to 
injury or death (6). Patient recruitment is one of the main 
barriers to conducting these studies. Performing a trial of 
all medical expertise, issues on inequality, representation, 
and access to health care services may raise problems in 
patient recruitment, but the barriers to research partner-
ships for minorities are through the frameworks of cultural 
and therapeutic misconception, poor health literacy, lack 
of trust in the therapeutic system, or fear of relevance of 
the experiments (7, 8). Even if the costs of randomized 
clinical trials are comparable to the costs of standard care, 
lack of insurance coverage will prevent entry or registra-
tion (6). 
The randomized clinical trials (RCTs) reviewed and 
published in leading journals are considered as the highest 
level of evidence in medicine. However, this is not always 
the case and RCTs, even when reported in these journals, 
can be misleading by 2 mechanisms: (1) timeliness or 
poor design in RCTs; (2) misinterpretation of even well-
designed RCTs. 
Several limitations may decrease the value of these 
studies: defects in patient selection, physician 
competence, randomization, applicability, endpoints, and 
the population being studied. Another problem with arti-
cles describing RCTs is the potential for the conclusions 
of the trial report to be misleading because of error or bi-
as. This together with subsequent misinterpretation of the 
trial results or conclusions by others can make the effect 
of the trial misleading with an unintended detrimental 
result on medical practice (9). 
Although the researcher may limit biasing through ran-
dom allocation or blinding methods, clinical trial results 
may still be less acceptable (3). 
Clinical trial studies have 4 steps of design, conducting, 
analysis, and reporting of results. Also, in these studies, 
different people are involved with different majors, which 
may result in some challenges associated with the condi-
tions of each country. Therefore, the aim of this study was 
to provide a comprehensive review of the challenges in 
conducting different steps of clinical trial studies (design, 
conducting, analysis, and reporting) in both developing 
and developed countries.  
 
Methods 
This systematic review was prepared and reported based 
on the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) checklist and flow diagram 
(10) (Fig. 1). 
All original articles presenting the barriers to clinical 
trial studies at one of the steps of design, conducting, 
analysis, and reporting of the results and meeting the in-
clusion and exclusion criteria have been included in this 
review. 
 
Inclusion criteria 
• Studies that reported challenges in 4 steps of clinical 
trials (design, conducting, analysis, reporting) 
• Studies published in English  
• Studies published during 1991-2017 
 
Exclusion criteria 
• Studies that reported clinical challenges in the con-
ducting of clinical trials in different areas of diseases. 
 
Search strategy 
The search syntax was developed based on PubMed 
(Medline) and included 45 related keywords and was 
modified based on other international databases. Data-
bases (Medline-PubMed, Embase, Web of Sciences, Sco-
pus, and Google Scholar) were sought for relevant scien-
tific evidence up to October 2017. The search strategy 
was limited to English articles published during 1991–
2017 (Table 1). 
 
Article screening and selection 
 In the first stage, titles and abstracts of all articles were 
evaluated by 2 researchers (FV, YM) independently. 
Then, full-texts were assessed to decide on relevancy of 
the articles. The researchers discussed the disagreement, 
if any, and in case an agreement was not reached, the 
third author (LJ) evaluated the study. 
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Quality Assessment  
The quality of each study was assessed according to 
Kuper (11). The criteria contain 6 major questions that 
address different key areas (design sample, data collec-
tion, analysis, reporting), each of which are answered as 
‘good’, ‘fair’, and ‘poor’. Based on the literature, a quali-
ty score was given for each question using the following 
definitions: Good: sufficient details are provided and well 
justified; fair: most information is given and justified but 
some information is missing; poor: no or few descriptive 
details are provided. The purpose of the quality assess-
ment was not to establish thresholds to exclude the stud-
ies, but rather to distinguish between studies in overall 
contribution to the review (12). 
 
Data extraction  
All papers included in the present study were evaluated 
independently by 2 researchers (FV, YM). They dis-
cussed the disagreements, if any, and in case an agree-
ment was not reached, a third author (LJ) evaluated the 
study. A structured checklist was used to extract the data 
on the (1) name of first author and title, (2) country, (3) 
year of publication, (4) recommendations, (5) priority 
populations, (6) focus, and (7) outcomes. Additional in-
formation on the study results was extracted with respect 
to type of instruments.  
Records identified through database 
searching  
(n = 9607) 
Additional records identified through 
other sources  
(n =30) 
Records after duplicates removed  
(n = 8760) 
Records screened  
(n = 8760) 
Records excluded  
(n =8688) 
Full‐text articles assessed for 
eligibility  
(n =72) 
Articles excluded after:  
Review articles: 5 
Articles without the 
inclusion criteria: 38  
Studies included in qualitative 
synthesis  
(n = 29)
 
Fig. 1. PRISMA 2009 flow diagram for study selection 
 
Table 1. Search strategy 
PubMed/Medline 
(“clinical trial”[tiab] OR “Clinical study” [tiab] OR “Controlled clinical trial” [tiab] OR “randomized clinical trial”[tiab] OR “randomized controlled trial” [tiab] 
OR “Cross Over Design” [tiab] OR “Cross Over Studies” [tiab] OR “Crossover procedure” [tiab] OR "Field Trial"[tiab] OR RCTs[tiab] OR “Community 
Trial” [tiab] OR “Factorial Design” [tiab] OR “Cluster randomized design” [tiab] OR “Open trial” [tiab] OR “open study” [tiab] OR “Mega trial” [tiab] OR 
“Intervention Studies” [tiab] OR “interventional study” [tiab] OR “intervention trial” [tiab] OR “interventional studies” [tiab] OR “Pragmatic Clinical Trial” 
[tiab] OR “Zelen’s design” [tiab] OR “Single Arm Trials” [tiab] OR “Parallel Group Design” [tiab] OR “parallel design” [tiab] OR “clinical epidemiology” 
[tiab]) AND (Barriers[tiab] OR Limitations[tiab] OR Problems[tiab] OR Challenges[tiab] OR Difficulties[tiab] OR mistakes[tiab] OR setback[tiab] OR 
hitch[tiab] OR trouble[tiab] OR hassle[tiab] OR Defects[tiab] OR Bugs[tiab] OR flaws[tiab] OR weaknesses[tiab] OR faults[tiab] OR restriction[tiab] OR 
imperfection[tiab] OR wrongs[tiab] OR blunders[tiab] ) AND 1991/01/01[DP]:2017/10/20[DP]) 
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Results 
In the first step, 9637 studies were evaluated, of which 
877 were duplicate articles and excluded. Then, 8760 re-
maining articles were evaluated based on their abstracts 
and 8688 irrelevant articles were excluded. In the next 
stage, full-texts were assessed and 43 articles were re-
moved. Finally, after examining the studies and applying 
the inclusion and exclusion criteria, 29 studies remained 
and their results were evaluated. The following barriers in 
different steps of randomized clinical trials were identi-
fied: investigator-initiated trials may face similar difficul-
ties with trials sponsored by international bodies. These 
difficulties will be related to handling of the regulatory 
bodies, administrative and financial bottlenecks, multiple 
languages, patient compensation options, interviewer 
compensation modalities, and additional documents re-
quired to facilitate data collection. Among the 4 stages of 
design, conducting, analysis, and reporting, the greatest 
challenges were related to conducting the randomized 
clinical trial. Challenges related to conducting were as 
follow: ethical and regulatory system obstacles (2, 5, 6, 
13-19); financial bottle necks (2, 5, 6, 14-16, 20-22); lack 
of skilled personnel (6, 14-16, 18, 21, 22); barriers to pa-
tient recruitment (5-7, 23-26); lack of infrastructure (5, 6, 
15, 16, 21, 22); lack of awareness and motivation (6, 15, 
16, 18, 27); lack of time (5, 14-16, 27); lack of knowledge 
of the general population (6, 24-27); lack of knowledge 
among the research professionals (25, 26, 28); lack of 
insurance coverage (24, 26); conflict of interest concerns 
(4, 25); lack of registry (28, 29); barriers to blinding (19, 
30); issues in compensation calculation (2, 6); administra-
tive bottle necks (2, 18); lack of integration between clin-
ical trials and patient care (20); lack of research environ-
ment (5); lack of transparency (17); lack of tools (20); 
operational hurdle (15); and multiple languages (2). Other 
challenges were poor planning (7, 20), lack of equipoise 
(25, 31) (design challenges), non-use of appropriate sta-
tistical methods for analysis (32) (analysis challenges) 
and challenges related to reporting which include selec-
tive reporting (3, 22), failure to report protocol (27, 33), 
incomplete data reporting (17), and difficulty in clinical 
trial report (29, 34) (Table 2). 
 
Discussion 
As clinical trials usually affect patient care and man-
agement more than other types of studies do, it is highly 
important to consider the highest standards for writing, 
conducting, analyzing, and reporting these studies (35). In 
this study, the literature on barriers facing clinical trial 
studies in different steps (design, conducting, analysis, 
reporting) were reviewed. The greatest barriers were ethi-
cal and regulatory system obstacles, financial bottlenecks, 
lack of skilled personnel, and barriers to patient recruit-
ment. In addition, several other challenges emerged from 
the research literature: lack of infrastructure, lack of 
awareness and motivation, lack of time, lack of 
knowledge among the general public, and lack of 
knowledge among the research professionals. By contrast, 
an article discussed the opportunities and challenges in 
conducting clinical trials globally. Informed consent, data 
quality, differences in medical practice, acceptability of 
foreign data, and ethical factors were global clinical trials 
challenges (36). A systematic review related to barriers 
for conducting clinical trials in developing countries indi-
cated that the greatest challenge that researchers faced in 
developing countries was lack of financial and human 
capacity (37). However, a systematic review on physician 
barriers in RCTs for cancer and other illnesses in the de-
Table 2. Barriers for designing, conducting, analyzing, and publishing clinical trials 
Barriers for designing, conducting, analyzing, and publishing clinical trials 
Reference Subthemes Thematic barriers 
(7, 20) Poor design Barriers for designing a clinical trial 
(25, 31) Lack of equipoise 
(2, 5, 6, 14-16, 20-22) Financial bottlenecks Barriers for conducting a clinical trial 
(24, 26) Lack of insurance coverage 
(25, 26, 28) Lack of knowledge among the research professionals 
(6, 24-27) Lack of knowledge among general public 
(2, 5, 6, 13-19) Ethical and regulatory system obstacles 
(6, 14-16, 18, 21, 22) Lack of skilled personnel 
(5) Lack of research environment 
(20) Lack of integration between clinical trials and patient care 
(2, 6) Issues in compensation 
(6, 15, 16, 18, 27) Lack of awareness and motivation 
(20) Lack of tools 
(17) transparency Lack of 
(5, 6, 15, 16, 21, 22) Lack of infrastructure 
(19, 30) Barriers to blinding 
(15) Operational hurdles 
(4, 25) Conflict of interest concerns 
(28, 29) Lack of registry 
(5-7, 23-26) Barriers to patient recruitment 
(2) Multiple languages 
(2, 18) Administrative bottlenecks 
(5, 14-16, 27) Lack of time 
(32) Lack of using appropriate statistical methods Barriers for analyzing a clinical trial 
(3, 22) Selective reporting Barriers for publishing a clinical trial 
(17) Incomplete reporting of data 
(29, 34) Difficulty in clinical trial report 
(27, 33) Failure to report protocol 
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veloped world identified lack of time as a major barrier 
(38). Another study discussed barriers to the conduct of 
randomized clinical trials within all disease areas. In that 
study, inadequate knowledge of clinical research and trial 
methodology, lack of funding, excessive monitoring, 
restrictive privacy law, lack of transparency, complex 
regulatory requirements, and inadequate infrastructures 
were barriers to randomized clinical trials (39).  
Ethical and regulatory barriers were the most 
commonly cited reasons reported in the included studies. 
Developed countries perform a number of clinical trials in 
developing countries. In developing countries, such as 
India, these trials indicated that most Indians do not have 
access to good quality and affordable care and therefore 
may accept offers that might provide better quality and 
free treatment. They were conducted on people who were 
vulnerable because they could not afford good quality 
treatment or the most effective drugs (6). On the other 
hand, medications that are experimented in clinical trials 
in developed countries may not be used by people in 
developing countries due to their high cost. This subject 
can be an ethical problem because there is a principle in 
clinical trials that says the benefits of clinical trials must 
be more than their disadvantages and people should 
benefit from the result of these studies. 
 Another challenge was financial bottlenecks, which is 
reflective of the 10/90 gap in which less than 10% of 
health research funds in the world are directed toward 
problems that affect 90% of the world’s population, and 
an even smaller percentage goes to fund researchers and 
health problems of developing countries (6, 40, 41). 
Funding for clinical trials in developing countries comes 
mostly from Western countries and the pharmaceutical 
companies based there (42). In most low-income 
countries, research is a luxury because of economic 
constraints (43). Scarce resources in developing countries 
are nearly all spent on program implementation, and 
allocating funds for research is almost out of the equation 
in most development plans. Contrary to existing beliefs 
and practices, the lack of resources in low- and middle-
income countries paradoxically increases the need for 
reliable health care evidence to prioritize the use of these 
scarce resources (44). 
Conducting clinical trials is essential for evaluating 
therapeutic interventions, but at the same time, taking 
care of patients is also of crucial importance. To address 
this necessity, numerous international statements and 
guidelines on protection of human subjects have been 
drafted and implemented. However, the results of a study 
conducted in India showed that in clinical research activi-
ty, because of the unique socioeconomic conditions in 
India (low literacy, poverty, general lack of medical facil-
ities) and the unique doctor-patient relationship, the pa-
tient ends up being the most vulnerable in the clinical trial 
process. The culture and socioeconomic conditions of any 
country and region may affect the quality and the stages 
of conducting a clinical trial. The regulatory guidelines 
are part of a dynamic process and will continue evolving 
based on the changing requirements and demands of the 
system. Therefore, these regulations must be carried for-
ward by proactively responding to such challenges with 
suitable clarifications and/or amendments without com-
promising the well-being of trial participants (6). 
Conducting clinical trials and obtaining informed con-
sent in any country are subject to the cultural conditions 
of that country. For example, the results of a study con-
ducted in sub-Saharan Africa showed that the collection 
of blood samples from individuals in clinical trial projects 
could be challenging and may be one of the considerable 
reasons for local rumors of "blood theft" or "blood sale". 
Such attitudes and cultures could potentially have a pro-
found effect on the success of research projects (45). Par-
ticipants’ knowledge is also highly important in properly 
implementing and collecting data of a clinical trial. To 
confirm these results, a study conducted in the United 
States showed that at least 40% of Americans did not un-
derstand the idea of a clinical trial. 
For various reasons, knowledge can be a major factor in 
participation. First, low knowledge or confusion about the 
key facts of trial methods (random allocation, informed 
consent, standard treatment) can disrupt participation 
(46). Secondly, patients are often reluctant to participate 
in something about which they have little knowledge 
(47).  
The lack of knowledge is not limited to patients. One of 
the most frequent probable reasons for the lack of report-
ing was lack of awareness and shortage of knowledge 
about clinical trials (48, 49). Prior to the conduction of 
trials, a protocol is conducted to specify the exact steps of 
the task. Due to the unpredictable nature of interventions 
in health sciences, some changes may occur during the 
implementation of the trials with respect to the approved 
protocols. Therefore, researchers need to include these 
changes in their reports (50). However, excessive defects 
of a protocol may result in patient damage and occurrence 
of errors in clinical trial outcomes. Although the CON-
SORT statement provides a comprehensive guide to pro-
tocol defect reports, the reports of studies are not com-
plete. Hence, as the first step to improve reporting, au-
thors are recommended to report protocol defects based 
on the CONSORT statement.  
The results of the studies indicated that most research-
ers lacked knowledge and awareness even in the early 
definitions of the principles of a trial. For example, a 
study by Schulz et al showed that most researchers failed 
to recognize blinding and allocation concealment, and this 
suggested their lack of knowledge (51). 
It is recommended that this issue be continually taught 
to researchers, as lack of knowledge may affect all stages 
of clinical trials and their outcomes. A study by White et 
al showed that knowledge rather than attitude is the lead-
ing factor impeding registration. Investigators were very 
unfamiliar with international registration tools other than 
clinicaltrials.gov (28). 
Registration of clinical trials may prevent publication 
bias and selective reporting, as the bias caused by selec-
tive reporting can affect meta-analyses work on the re-
sults of systematic reviews and evidence-based studies, 
leading to giving incorrect answers to important clinical 
questions. Patients, doctors, and health policymakers rely 
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on this information in their evidence-based decision mak-
ing (3). Thus, according to WHO, registration of a clinical 
trial is "a scientific, ethical and moral responsibility" (52). 
It is, therefore, highly important to promote the registra-
tion of clinical trials as part of the national research poli-
cy. However, a study conducted in Argentina showed that 
the current percentages of internationally registered trials 
and participants' responses were insufficient to achieve 
the desired goals (28). It is important that all registrations, 
including integrated information elements, be electroni-
cally and widely searchable (53). 
It should always be taken into consideration that clini-
cal trial management is a public responsibility and re-
quires a deep understanding of statistical methods. 
This systematic review had limitations and strengths. It 
provided a comprehensive presentation of the challenges 
of clinical trial studies in different steps including design, 
conducting, analysis, and reporting, in both developing 
and developed countries. Because of the limited number 
of articles in the review, the study did not examine the 
similarities and differences between barriers among the 
different countries. Most of the included studies were 
qualitative. Those articles not written in English were ex-
cluded, as because the cost of translation was not feasible.  
 
Conclusion 
Among the 4 stages of design, conducting, analysis, and 
reporting, the most challenges were related to conduct of 
randomized clinical trial. The main barriers identified in 
the present systematic review were as follow: barriers 
related to handling ethical and regulatory systems, patient 
recruitment, lack of budget and skilled staff, lack of infra-
structure, lack of knowledge among the general public, 
lack of awareness and motivation, and lack of time for 
conducting clinical trials. Barriers may vary widely de-
pending on the context in which the clinical trials are 
conducted. There are several intercountry differences in 
culture, socioeconomic, and political contexts. Thus, find-
ings of this review may not reflect the situation in any 
specific country. Providing training in different steps and 
levels to improve the quality of randomized clinical trial 
studies was the most important recommendation in these 
studies. 
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